Format
Items per page
Sort by

Send to:

Choose Destination

Results: 17

Related Articles by Review for PubMed (Select 23442322)

1.

HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab.

Ithimakin S, Day KC, Malik F, Zen Q, Dawsey SJ, Bersano-Begey TF, Quraishi AA, Ignatoski KW, Daignault S, Davis A, Hall CL, Palanisamy N, Heath AN, Tawakkol N, Luther TK, Clouthier SG, Chadwick WA, Day ML, Kleer CG, Thomas DG, Hayes DF, Korkaya H, Wicha MS.

Cancer Res. 2013 Mar 1;73(5):1635-46. doi: 10.1158/0008-5472.CAN-12-3349. Epub 2013 Feb 26.

2.

HER2 and breast cancer stem cells: more than meets the eye.

Korkaya H, Wicha MS.

Cancer Res. 2013 Jun 15;73(12):3489-93. doi: 10.1158/0008-5472.CAN-13-0260. Epub 2013 Jun 5. Review.

3.

A systematic review of dual targeting in HER2-positive breast cancer.

Kümler I, Tuxen MK, Nielsen DL.

Cancer Treat Rev. 2014 Mar;40(2):259-70. doi: 10.1016/j.ctrv.2013.09.002. Epub 2013 Sep 11. Review.

PMID:
24080156
4.
5.

[Trastuzumab in early breast cancer].

Ismaili N, Elmajjaoui S, Tahri A, Benjaafar N, Errihani H, Belbaraka R.

Presse Med. 2013 Jul-Aug;42(7-8):1069-80. doi: 10.1016/j.lpm.2013.01.054. Epub 2013 Apr 8. Review. French.

PMID:
23578469
6.

Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer.

Chung C, Lam MS.

Am J Health Syst Pharm. 2013 Sep 15;70(18):1579-87. doi: 10.2146/ajhp120735. Review.

PMID:
23988598
7.

Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer.

Chang HR.

Cancer. 2010 Jun 15;116(12):2856-67. doi: 10.1002/cncr.25120. Review.

8.

Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines.

Hirsch FR, Helfrich B, Franklin WA, Varella-Garcia M, Chan DC, Bunn PA Jr.

Clin Breast Cancer. 2002 May;3 Suppl 1:12-6. Review.

PMID:
12057039
9.

Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer.

Niculescu-Duvaz I.

Curr Opin Mol Ther. 2010 Jun;12(3):350-60. Review.

PMID:
20521224
10.

HER2 overexpressing metastatic breast cancer.

Spigel DR, Burstein HJ.

Curr Treat Options Oncol. 2002 Apr;3(2):163-74. Review.

PMID:
12057079
11.

A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.

Larsen PB, Kümler I, Nielsen DL.

Cancer Treat Rev. 2013 Nov;39(7):720-7. doi: 10.1016/j.ctrv.2013.01.006. Epub 2013 Mar 5. Review.

PMID:
23481218
12.

The adjuvant treatment of HER2-positive breast cancer.

Jelovac D, Wolff AC.

Curr Treat Options Oncol. 2012 Jun;13(2):230-9. doi: 10.1007/s11864-012-0186-4. Review.

PMID:
22410709
13.

HER2-positive breast cancer: update on Breast Cancer International Research Group trials.

Nabholtz JM, Reese DM, Lindsay MA, Riva A.

Clin Breast Cancer. 2002 Oct;3 Suppl 2:S75-9. Review.

PMID:
12435291
14.

Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?

Constantinidou A, Smith I.

Breast. 2011 Oct;20 Suppl 3:S158-61. doi: 10.1016/S0960-9776(11)70316-2. Review.

PMID:
22015286
15.

Overcoming treatment resistance in HER2-positive breast cancer: potential strategies.

Puglisi F, Minisini AM, De Angelis C, Arpino G.

Drugs. 2012 Jun 18;72(9):1175-93. doi: 10.2165/11634000-000000000-00000. Review.

PMID:
22686613
16.

Targeting breast cancer initiating cells: advances in breast cancer research and therapy.

McCubrey JA, Davis NM, Abrams SL, Montalto G, Cervello M, Libra M, Nicoletti F, D'Assoro AB, Cocco L, Martelli AM, Steelman LS.

Adv Biol Regul. 2014 Sep;56:81-107. doi: 10.1016/j.jbior.2014.05.003. Epub 2014 May 22. Review.

PMID:
24913694
17.

Mimicking breast cancer-induced bone metastasis in vivo: current transplantation models and advanced humanized strategies.

Thibaudeau L, Quent VM, Holzapfel BM, Taubenberger AV, Straub M, Hutmacher DW.

Cancer Metastasis Rev. 2014 Sep;33(2-3):721-35. doi: 10.1007/s10555-014-9499-z. Review.

PMID:
24771149
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk